<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04102319</url>
  </required_header>
  <id_info>
    <org_study_id>hepcidin,Anemia</org_study_id>
    <nct_id>NCT04102319</nct_id>
  </id_info>
  <brief_title>Serum Hepcidin, Haemoglobin Level and Iron Status in Chronic Kidney Disease Patients (CKD) With Anaemia</brief_title>
  <official_title>Association Between Hepcidin, Haemoglobin Level and Iron Status in Stage 4 Chronic Kidney Disease Patients With Anaemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The current study is planned to assess possible relationships of serum hepcidin levels with
      haemoglobin levels, inflammation and iron statuses in stage 4 CKD patients.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 1, 2019</start_date>
  <completion_date type="Anticipated">December 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>relation between serum hepcidin level and ESR ckd stage 4</measure>
    <time_frame>at study entry and then again after 3 months</time_frame>
    <description>measure strength of relation, r, between levels of serum hepcidin and ESR, an inflammation marker</description>
  </primary_outcome>
  <primary_outcome>
    <measure>relation between serum hepcidin and serum ferritin levels</measure>
    <time_frame>at study entry and then again after 3 months</time_frame>
    <description>measure strength of relation, r, between levels of hecidin and ferritin</description>
  </primary_outcome>
  <enrollment type="Anticipated">64</enrollment>
  <condition>CKD Stage 4</condition>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>serum hepcidin</intervention_name>
    <description>it is a serum marker</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adult patients with chronic kidney disease stage 4 who have anemia with hemoglobin level
        below 11 gm/dl
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients (&gt;18 years) with anaemia who had CKD stage 4 with glomerular filtration
             rate (GFR) 15-29 ml/min/1.73 m2

        Exclusion Criteria:

          -  Subjects with blood transfusion within the preceding 3 months. myocardial infarction
             (MI) history within the preceding 3 months, surgical history within the preceding 3
             months, malignancy. Advanced liver cirrhosis. uncontrolled diabetes
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mohamed Hamed, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assiut University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Deiaaeldeen Mohamed, master degree</last_name>
    <phone>+201032997001</phone>
    <email>deiaa_1981@yahoo.com</email>
  </overall_contact>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>September 19, 2019</study_first_submitted>
  <study_first_submitted_qc>September 22, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 25, 2019</study_first_posted>
  <last_update_submitted>September 22, 2019</last_update_submitted>
  <last_update_submitted_qc>September 22, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 25, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Deiaaeldeen Masaoud Sadeq Mohammed</investigator_full_name>
    <investigator_title>Dr</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepcidins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

